股骨头坏死患者生活质量临床研究

目的探讨股骨头坏死(ONFH)患者的生活质量及影响因素,为ONFH的治疗选择提供依据;探讨将生活质量作为其疗效评价的可行性。方法采用国际通用的SF-36量表对95例ONFH的住院患者和60例正常对照人群进行测量评分。155份量表的填写均为被调查者本人完成。95例ONFH患者按ARCO分期:Ⅰ期4例,Ⅱ期54例,Ⅲ期32例,Ⅳ期5例。界定Ⅰ～Ⅱ期为早期,Ⅲ～Ⅳ期为中晚期。将性别、年龄、职业、婚姻状况、文化程度、家庭收入等非疾病因素作为自变量,通过t检验、方差分析、多元逐步回归分析ONFH患者的生活质量及其影响因素。结果 ONFH组生活质量评分分别为躯体功能(PF)(69.42±16.16)分;躯体健康所致角色限制(RP)(24.11±34.91)分;躯体疼痛(BP)(67.02±14.36)分;总体健康(GH)(54.21±22.79)分;活力(VT)(65.42±22.65)分;社会功能(SF)(66.08±26.00)分;情绪问题所致角色限制(RE)(55.44±43.11)分;心理健康(MH)(65.73±18.96)分与正常组进行比较,差异有统计学意义(P0.01);早期和中晚期患者的PF、RP评分分别为(72.46±11.41)、(64.87±20.71)分和(19.74±31.60)、(38.16±37.10)分,差异有统计学意义(P0.05);非疾病因素对生存质量各维度均有影响,特别是文化程度和婚姻状况。结论生活质量的评价为ONFH治疗方法的选择提供了依据,把生活质量引入ONFH的疗效评价体系将更具有人性化。     

Quality of life outcomes in 599 cancer and non-cancer patients with colostomies

BACKGROUND: A colostomy is known to impact negatively on a patient's quality of life (QOL). Concerns include incontinence, rectal discharge, gas, difficulties in returning to work, decreased sexual activity, and travel and leisure challenges. Reports have described QOL outcomes in cancer patients with colostomies and inflammatory bowel syndrome with colostomies, but little has been written regarding a comparison of cancer and non-cancer populations. The purpose of this study was to describe QOL issues of colostomy patients and compare these issues in cancer and non-cancer participants. MATERIALS AND METHODS: A QOL-ostomy questionnaire was mailed to 2455 California members of the United Ostomy Association. RESULTS: Of the 1457 respondents (59%), 599 had a colostomy. Most were results from cancer (517/599), with colorectal cancer being the most common diagnosis. The most common benign diagnoses were inflammatory bowel disease and diverticulitis. Demographics were similar, except for more females in the non-cancer group (76%), and increased length of time with colostomy from the cancer group (mean 135.9 versus 106.4 months, P = 0.03). Common QOL problems included sexual problems, gas, constipation, travel difficulties, and dissatisfaction with appearance. Overall, cancer patients had less difficulty adjusting to their colostomies. CONCLUSIONS: Results confirmed the negative impact of a colostomy on QOL. While patients with cancer had a better overall QOL than those with benign processes, concerns were common to all colostomy patients. These results provide health care practitioners with information useful in discussing QOL concerns during pre-operation treatment decisions and post operative teaching and follow-up care.     

A Meta-Analysis of Quality of Life for Abdominoperineal Excision of Rectum versus Anterior Resection for Rectal Cancer

Background Avoiding a permanent stoma following rectal cancer excision is believed to improve quality of life (QoL), but evidence from comparative studies is contradictory. The aim of this study was to compare QoL following abdominoperineal excision of rectum (APER) with that after anterior resection (AR) in patients with rectal cancer. Methods A literature search was performed to identify studies published between 1966 and 2006 comparing values of QoL following APER and AR. Random-effect meta-analysis was used to combine the data. Sensitivity analyses were performed for larger studies, those of higher quality and those using self-administered QoL questionnaires. Results The outcomes for 1,443 patients from 11 studies, of whom 486 (33%) underwent APER, were included. QoL assessments were made at periods of up to 2 years following surgery. There was no significant difference in global health scores between APER and AR. Vitality (WMD −9.82; 95% CI −27.01, −2.04, P = 0.01) and sexual function (WMD −2.73; 95% CI −4.93, −0.64, P = 0.01) were improved in the AR patients. Patients with low AR had improved physical function scores in comparison with APER patients (WMD −4.67; 95% CI −9.10, −0.23; P = 0.004). Cognitive (WMD 3.57; 95% CI 1.41, 5.73; P < 0.001) and emotional function scores (WMD 3.51; 95% CI 1.40, 5.62; P < 0.001) were higher for APER patients. Conclusion Overall, when comparing APER with AR, we identified no differences in general QoL following the procedures. Individualisation of care for rectal cancer patients is essential, but a policy of avoidance of APER cannot currently be justified on the grounds of QoL alone.     

Quality of life in women with stress urinary incontinence

The objective of this study was to identify clinical and demographic factors associated with incontinence-related quality of life (QoL) in 655 women with stress urinary incontinence who elected surgical treatment. The following factors were examined for their association with QoL as measured with the Incontinence Impact Questionnaire (IIQ): number of incontinence (UI) episodes/day; self-reported type of UI symptoms (stress and urge); sexual function as measured by the Prolapse/Urinary Incontinence Sexual Questionnaire; symptom bother as measured by the Urogenital Distress Inventory; as well as other clinical and sociodemographic factors. A stepwise least-squares regression analysis was used to identify factors significantly associated with QoL. Lower QoL was related to the greater frequency of stress UI symptoms, increasing severity, greater symptom bother, prior UI surgery or treatment, and sexual dysfunction (if sexually active). Health and sociodemographic factors associated with lower incontinence-related QoL included current tobacco use, younger age, lower socioeconomic status, and Hispanic ethnicity. Supported by cooperative agreements from the National Institute of Diabetes and Digestive and Kidney Diseases, with additional support from the National Institute of Child Health and Human Development and the Office of Research on Women’s Health, National Institutes of Health.     

The Effect of <Emphasis Type="Italic">LRP5</Emphasis> Polymorphisms on Bone Mineral Density Is Apparent in Childhood

Paget’s disease of bone (PDB) can adversely affect quality of life, but relatively little is known about the clinical predictors of reduced quality of life in patients with the disease. Here, we studied quality of life and its determinants in a large cohort of PDB patients who had been enrolled into the PRISM study, a randomized comparative trial of intensive versus symptomatic treatment for PDB. Health-related quality of life was assessed using the Short-Form 36 (SF36) questionnaire and other validated assessment instruments in 1,324 subjects with PDB. Clinical predictors of quality of life were identified by multivariate regression analysis. The physical summary (mean ± standard deviation) score of the SF36 was substantially reduced in PDB to 36.3 ± 11.3 compared with the expected population norm of 50 (P < 0.001). The mental summary score was only slightly reduced, to 48.7 ± 11.8, in PDB; but this was statistically significant (P < 0.001). Bone pain due to PDB, previous bisphosphonate therapy, and increasing age were identified as negative predictors of the SF36 physical summary score (P < 0.001); but serum levels of total alkaline phosphatase (ALP) did not predict physical summary score. We conclude that PDB has a substantial negative impact on health-related quality of life, which mainly affects physical functioning. The lack of correlation between ALP and quality of life observed in this study emphasizes the importance of addressing quality-of-life issues when treating PDB and not just focussing on response of ALP levels. The PRISM Trial Group. Writing Group: Marion K. Campbell, William D. Fraser, Anne L. Langston, Graeme MacLennan, Stuart H. Ralston, Peter L. Selby. Independent Trial Steering Committee: Maarten Boers (chair), Juliet Compston (member), Philip Hannaford (observer, host institution representative), Marilyn McCallum (member), Graham Russell (member). Data Monitoring Committee: Ade Adebajo, Nigel Arden, Howard Bird, Margaret Byron, Alison Carr, Ernest Choy (chair 2001–06), Peter Croft, Vern Farewell, Ian Harvey, Sarah Hewlett, Shabbar Jaffar, Martyn Lewis, Gary MacFarlane (chair 2006), Chris Roberts, Lee Shepstone, Deborah Symmons. Trial Office Team: Gary Adams (data manager), Daniel Barnett (trial programmer), Marie Cameron (research assistant), Janice Cruden (data manager), Magnus McGee (trial statistician), Donna Patterson (data manager), Clare Robertson (research assistant), Allan Walker (trial programmer), Euan Wiseman (trial programmer). Local Trial Investigators (the following people were responsible for the local coordination of the study at the collaborating hospital sites, *lead consultant): Aberdeen Royal Infirmary, UK, Vera Herd, Stuart H. Ralston*; University Hospital Aintree, UK, Rose McIver, Mashood Siddiqi*; Royal National Hospital for Rheumatic Disease, Bath, UK, Ashok Bhalla,* Diana Cochran, Sharon Grieve, Sara Mills; Musgrave Park Hospital, Belfast, UK, Katrina Hughes, Richard Wallace*; Queen Elizabeth Hospital, Birmingham, UK, Neil Gittoes,* Liz McGregor; Royal Bolton Hospital, UK, Keatley R. H. Adams,* Mary Adams; Ninewells Hospital, Dundee, UK, Vera Herd, Graham Leese,* Ellen Malcolm; University Hospital of North Durham, UK, Sarah Hailwood*; Medway Maritime Hospital, Gillingham, UK, Paul Ryan,* Gwen Worcester; Western Infirmary, Glasgow, UK, Alastair McLellan,* Debby Nelson; Huddersfield Royal Infirmary, UK, Allan Fairclough, Richard Reece*; Raigmore Hospital, Inverness, UK, Fiona McGhie, Malcolm Steven*; Airedale Hospital, Keighley, UK, Annie Cooper,* Stuart H. Ralston*; Leicester Royal Infirmary and Leicester General Hospital, UK, Margaret Coe, S. Javed Iqbal,* Geraldine McHugh; Royal Liverpool University Hospital, UK, William D. Fraser,* Ya-Wen Jessica Huang, Margaret Little, Vinita Mishra, Nicola Wherly; Llandudno General Hospital, UK, Merle Maddison, Lyn Vaterlaws*; Guy’s Hospital, London, UK, Ignac Fogelman,* Nina Prescod; King’s College Hospital, London, UK, Rama Chandra, Tina Mangion, Caje Moniz*; Manchester Royal Infirmary, UK, Susan Harrison, Peter L. Selby*; James Cook University Hospital, Middlesbrough, UK, John N. Fordham,* Val Lunn, Dawn Youll; Freeman Hospital, Newcastle, UK, Roger Francis*; Norfolk & Norwich University Hospital, UK, Jane Leeder, David G. I. Scott*; City Hospital, Nottingham, UK, David Hosking,* Pat San; Robert Jones & Agnes Hunt Orthopaedic Hospital, Oswestry, UK, Michael Davie,* Teresa Jones, Dawn Pugh; Nuffield Orthopaedic Centre, Oxford, UK, Matthew Brown, Vicky Toghill, John Wass,* Jo Young; Llandough Hospital, Penarth, UK, Roz Broadbent, Mike Stone,* Jane Turton; Derriford Hospital, Plymouth, UK, Charles Hutton,* Maggie Jolly; Poole Hospital, UK, Julia Taylor, Paul Thompson*; Harold Wood Hospital, Romford, UK, Kuntal Chakravarty*; Oldchurch Hospital, Romford, UK, Christine Heron, Christopher Kelsey*; Hope Hospital, Salford, UK, Sylvia Mercer, Terence W. O’Neill*; Northern General Hospital, Sheffield, UK, Jenny Cliffe, Linda Kersh, Eugene McCloskey*; Southampton General Hospital, UK, Trish Byng, Janet Cushnaghan, Cyrus Cooper,* Nick Harvey, Karen Walker-Bone; Royal National Orthopaedic Hospital, Stanmore, UK, Richard Keen,* Maggie Partridge; Great Western Hospital, Swindon, UK, Lynne Kerton, Elizabeth Price*; Queen Elizabeth II Hospital, Welwyn Garden City, UK, Jill Lomas, Peter Winocour*; Arrowe Park Hospital, Wirral, UK, E. George, T. D. Kennedy,* Anthony Lake; Yeovil District Hospital, UK, Nita Beacham, Clare Buckley, Jenny Knight, Lisa Martin, T. G. Palferman.*     

放射治疗流程再造及质量控制

目的对放射治疗流程进行再造与优化并对放射治疗的各个环节进行全面质量控制,使放射治疗的效率提高、差错率降低。方法通过对放射治疗各环节进行分析,对放射治疗流程进行再造。结果实施放射治疗流程再造及质量控制后,每月工作量与上年同期对比增长60%,放射治疗综合满意度提高了25.8%。结论放射治疗流程再造及质量控制,可以使放射治疗的效率提高、差错率降低。     

瑞芬太尼、芬太尼对过度肥胖患者麻醉效果及麻醉复苏质量的影响

目的 探讨芬太尼和瑞芬太尼对于肥胖患者全身麻醉效果及复苏的影响,探索联合应用两种药物的可行性,并找到较为可行的联合方式.方法 按随机区组设计将实施全身麻醉的肥胖患者分为4组,每组20例,分别是芬太尼组(F组),瑞芬太尼组(R组),芬太尼复合瑞芬太尼l组(RF1组)和芬太尼复合瑞芬太尼2组(RF2组),比较4组患者的全身...     

Socio-economic and clinical factors predictive of paediatric quality of life post burn

Burns represent the second most common cause of non-intentional death in children under the age of five. Burns are amongst the most traumatic injuries and may impose significant psychological, educational, social and future occupational limitations to the young child.This cross-sectional study aimed to determine the socio-economic and clinical factors which predict quality of life in children with burn in a burns unit in South Africa.The Paediatric Quality of Life Inventory (PedsQL) and the Household Economic and Social Status Index (HESSI) questionnaires were administered to children and their caregivers one week and three months post discharge from the Johnson and Johnson Paediatric Burns Unit, Chris Hani Baragwanath Hospital, Soweto.The improvement in the PedsQL scores suggests that the quality of life for children three months after discharge is good despite being burnt. The severity of the burn was found to be a significant predictor of quality of life (p = 0.00). Poor socio-economic status was clearly evident in demographic data of the subjects.The findings from this study are particularly important in identifying areas for further research that would be beneficial to developing countries. Furthermore, the results are important in the move towards more holistic care for paediatric burn survivors.     

Quality of life of adult patients with severe burns

Background

Burns are one of the most significant health problems throughout the world, leading to prolonged hospitalisation and hence increased expense for the patients, their families and society. Today, the prognosis of patients with burns is dependent, apart from adequate treatment, upon the health-care system and health-care professionals, regarding not only survival, but also lifelong quality of life. This study aims to assess quality of life of adult patients with severe burns.

Patients and methods

This study was conducted on 100 adult patients with severe burns in the burn outpatient clinic (male and female) at Mansoura University Hospital. Parameters of burn and Burn Specific Health Scale (BSHS-B) were used to assess quality of life following burns.

Results

The study revealed that burns has negative impact on most dimensions of the quality of life of patients with burns.

Conclusions

The quality of life for people who have sustained a burns should be recognised and valued by the burn team in all phases of burn care.     

胰酶制剂对全胃切除术后患者生活质量的影响

目的 研究补充外源性胰酶是否可以改善胃癌患者行全胃切除术后的生活质量.方法 将106例符合试验要求的患者分为试验组和对照组,每组53例.试验组予口服胰酶胶囊,对照组不用胰酶.每例患者在术后6个月时填写1次EORTC QLQ-C30问卷和Korenaga问卷,并测定粪便脂肪含量.比较两组患者手术后各项评分是否有统计学差异,评价补充外源性胰酶是否可以改善患者的生活质量,同时通过分析粪便脂肪含量来评估其对患者术后脂肪泻的影响.结果 术后6个月时86例患者接受评价,通过EORTCQLQ-C30和Korenaga评分系统对患者手术后生活质量的评估和粪便脂肪含量的分析显示,通过补充外源性胰酶可以减少体重丢失,缓解食欲减退、失眠、疲劳、餐后饱胀、恶心、呕吐和腹泻等症状,并且改善肠道对脂肪的耐受性及患者健康状况.结论 全胃切除引起胰腺外分泌功能障碍,通过补充外源性胰酶可以改善患者术后的生活质量.